Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial
Ernst-Rüdiger Kuse, Oliver A. Cornely(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Heike Diekmann-Berndt(Astellas Pharma (Japan)), Sonja Koblinger(Astellas Pharma (Japan)), Clóvis Arns da Cunha, Didier Pittet(Hôpital Beau-Séjour), Ploenchan Chetchotisakd(Khon Kaen University), Antonio Freire(Grupo Santa Casa de Belo Horizonte), V Ramasubramanian(Apollo Hospitals), Amorn Leelarasamee(Siriraj Hospital), Olivier Lortholary(Hôpital Necker-Enfants Malades), Luis Ostrosky‐Zeichner(The University of Texas Health Science Center), Ignace Demeyer(Onze Lieve Vrouwziekenhuis Hospital), Markus Ruhnke(Radboud University Nijmegen), Johan Decruyenaere(Ghent University Hospital), Carlos H. Barrios(Eastern Cooperative Oncology Group), Jagdev Singh Sekhon(Fundación Instituto Valenciano de Oncología), Márcio Nucci(Universidade Federal do Rio de Janeiro), Frédérique Jacobs(Université Libre de Bruxelles), Andrew J. Ullmann(University of Würzburg)
Cited by 689
Related Papers
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
|Clinical Infectious Diseases|2015|4k
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k